RxDoctor Payments Data

Miguel Palacios-Mercado, MD

Internal Medicine · Caguas, PRNPI 1568497949

Payments from drug & device makers

$461in general payments, 2019–2025

Across 22 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$145
  • Johnson & Johnson$100
  • Medtronic$72
  • Lilly USA, LLC$41
  • Astellas Pharma US Inc$29
  • PBG Puerto Rico LLC$22
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$145
Johnson & Johnson5$100
Medtronic1$72
Lilly USA, LLC2$41
Astellas Pharma US Inc1$29
PBG Puerto Rico LLC1$22
Abbott1$20
Sanofi-aventis U.S. LLC1$17
Merck1$15

How this compares

$461 in reported general payments places this provider in the 45th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,660
Medicare patients
14
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban103$89,702
EliquisApixaban68$65,201
SynthroidLevothyroxine Sodium627$60,083
FarxigaDapagliflozin Propanediol68$59,965
LinzessLinaclotide58$56,659
JanuviaSitagliptin Phosphate41$52,832
JardianceEmpagliflozin27$28,942
Candesartan Cilexetil210$23,619
Diclofenac Potassium171$18,184
TrulicityDulaglutide16$17,657
JanumetSitagliptin Phos/Metformin Hcl13$17,172
SynjardyEmpagliflozin/Metformin Hcl18$16,403
OzempicSemaglutide15$14,645
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid82$12,640
Tolterodine Tartrate ErTolterodine Tartrate151$11,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$100$89,702103 claims
MerckJanuvia, Janumet$15$70,00454 claims
AstraZenecaFarxiga$145$59,96568 claims
Lilly USA, LLCTrulicity, Humulin N$41$20,52045 claims
Sanofi-aventis U.S. LLCLantus$17$11,35872 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →